News
Xiromed LLC Launches Estradiol Valerate Injection, USP
Press Release Florham Park, NJ, May 1st, 2023 Xiromed LLC today announced that the U.S. Food and Drug Administration (FDA) has granted approval to its Abbreviated New Drug Application (ANDA) for Estradiol Valerate Injection, USP, generic to Delestrogen®. Xiromed’s Estradiol Valerate Injection, USP is available in 3 strengths: 10mg/mL (5mL), 20mg/mL (5mL) and 40mg/mL (5mL). […]
Xiromed LLC Launches Testosterone Cypionate Injection, USP
Press Release Florham Park, NJ, April 13th, 2023 Xiromed LLC today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Testosterone Cypionate Injection, USP, generic to Depo-Testosterone®. Xiromed will launch immediately. Annual market sales for Depo-Testosterone® and its generics for the twelve-month […]
Xiromed LLC Launches Estradiol Transdermal Gel 0.1% with a Competitive Generic Therapy (CGT) Designation
Florham Park, NJ, October 11th, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Estradiol Transdermal Gel 0.1%, generic to Divigel®. Xiromed received final approval for its Abbreviated New Drug Application (ANDA) from the United States FDA with Competitive Generic Therapy (CGT) designation and is eligible for 180 […]
Xiromed LLC Launches Fulvestrant Injection 250 mg/5 mL (50 mg/mL)
Florham Park, NJ, September 12th, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fulvestrant Injection 250 mg/5 mL (50 mg/mL), generic to Faslodex®. Annual market sales for Faslodex® and its generics for the twelve-month period ending July, 2022 were $101.4 million, according to IQVIA™. Rob Spina, CEO […]
Xiromed LLC Launches Progesterone Vial for Injection 500 mg/10 mL (50mg/mL)
Florham Park, NJ, May 2nd, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Progesterone Injection USP, 500 mg/10 mL (50 mg/mL) Multiple-Dose Vial, generic to Progesterone Injection USP, 50 mg/mL. Annual market sales for Progesterone Injection USP, 50 mg/mL and its generics for the twelve month period […]
Xiromed® LLC Launches Naftifine Hydrochloride Cream USP, 2%
Florham Park, NJ, February 25th, 2022 Xiromed LLC, an Insud Pharma company, today announced the launch of Naftifine Hydrochloride Cream USP, 2%, generic to Naftin®, in partnership with Genzum Life Sciences. “Xiromed continues to execute on its growth plan to deliver quality generics to the US market. The launch of Naftifine Cream further bolsters our […]
Xiromed LLC Launches Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL)
Florham Park, NJ, January 24, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL), generic to Nitropress®. Xiromed CEO, Narasimhan Mani commented, “The launch of Sodium Nitroprusside Injection is Xiromed’s latest offering from our pipeline of injectable products and demonstrates […]
Xiromed LLC Launches Docetaxel Injection, USP, 10mg/mL
Florham Park, NJ, September 27, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fluorouracil Injection 50mg/mL, generic to Adrucil®. Annual market sales for Adrucil® and its generics for the twelve-month period ending June, 2021 were $22.2 million, according to IQVIA™. Xiromed CEO, Narasimhan Mani commented, “The […]
Xiromed LLC Launches Fluorouracil Injection 50mg/mL
Florham Park, NJ, August 12, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fluorouracil Injection 50mg/mL, generic to Adrucil®. Annual market sales for Adrucil® and its generics for the twelve-month period ending June, 2021 were $22.2 million, according to IQVIA™. Xiromed CEO, Narasimhan Mani commented, “The […]